A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of 6-Grasses in patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma
Latest Information Update: 26 Feb 2020
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Adverse reactions
- Acronyms ONSeT
- Sponsors Allergopharma
- 01 Jan 2020 Status changed to completed.
- 01 Jan 2020 Results (n=77) assessing safety and tolerability in patients with moderate to severe allergic rhinitis, published in the International Archives of Allergy and Immunology.
- 06 Oct 2018 This trial has been completed in Germany .